Common diseases and/or their consequences, including hypertension and susceptibility to end-organ damage, have genetic components. Contrary to hereditary mendelian diseases (where the existence of a rare mutation within a single gene usually dictates whether signs of the disease are present), the manifestations of common diseases correspond with what is defined in genetics as “quantitative complex traits.” Such traits within populations show continuous variation from low to high values and are shaped by the interactions of a great number of genes (each typically having small effects on their own) with environmental factors. Consequently, identification of genetic variants contributing to complex traits must rely on methods that are different than those used for the identification of mendelian genetic mutations (which can be performed by following within pedigrees the hereditary transmission of markers linked to the mutated gene). Among several available tools, genetic animal models have proven particularly useful to identify the effects of naturally occurring genetic variants and their interactions with environmental factors. Indeed, inbred strains are organisms that carry identical copies of each gene. Accordingly, it is possible by performing crosses between them to reduce the complexity of the problem, because the progeny of crosses will carry only 2 possible variants of any gene, and experimental and environmental conditions can be controlled.

**Complex Traits and Genetic Animal Models**

The pioneering work of Lewis K. Dahl constitutes an early and illustrative example of the use of such models. Dahl had hypothesized from epidemiological studies in human populations that elevated blood pressure may arise from the combination of high dietary salt with individual genetic susceptibility factors. To test that hypothesis experimentally, Dahl began a breeding program where he fed outbred rats with highly salted food. Because some rats developed high blood pressure in response to a high-salt diet but others did not, he selected breeders on the basis of their response to the salt challenge, and, within 3 generations, he obtained the clearly separated salt-sensitive (S) and salt-resistant (R) rat lines. Subsequently, Rapp developed inbred strains from Dahl’s outbred stocks. This general 2-step procedure (phenotypic-driven selection of breeders in outbred stocks followed by inbreeding of strains with desired characteristics) has constituted the basis for the creation of several models of inbred hypertensive strains that can be compared with normotensive counterparts, the most widely used ones arguably being the spontaneously hypertensive rats (SHRs) and their Wistar-Kyoto (WKY) normotensive counterparts. Among hypertensive models, some investigators have also developed strains that are more sensitive to end-organ damage, as, for instance, the SHR stroke-prone and the SHR heart failure strains.

In addition to having higher blood pressure, SHRs also display higher levels of locomotor activity than WKYs. To test whether this trait cosegregates with hypertension, Hendley and Ohlsson performed a phenotypic-driven selection of the progeny of SHR/WKY crosses and, thus, generated 2 novel inbred strains: the WKY-derived hypertensive (WKHA) and the WKY-derived hypertensive rats. A posteriori, it now appears that the designation of the WKHA strain may be partly misleading: indeed, SHRs and WKHA rats display higher locomotor activity than WKYs, but the difference is attributable mostly to the fact that WKYs are markedly hypoactive in comparison with many other rat strains. Nonetheless, one additional useful trait of WKHA rats is that, although both strains have normal and equivalent levels of blood pressure, they show the characteristics of concentric left ventricular (LV) hypertrophy (LVH) in comparison with WKYs. This phenotypic difference between the strains was exploited in the genetic studies described below.

**LV Mass and Natriuretic Peptides**

Since it was first reported in 1990 by the Framingham Heart Study, the importance of increased LV mass (LVM) has repeatedly been recognized as an important and independent risk factor that correlates very closely with cardiovascular risk and has strong prognostic implications. The fact that genetic factors contribute importantly to the variance of LVM is underlined by its...
high heritability (in fact, >50% in most studies). To identify natural genetic variants that contribute to the variance of LVM, we, therefore, studied the progeny of WKHA/WKY crosses to identify quantitative trait loci that link to LVM. Even before completing the linkage study, we observed that there was a negative correlation between LVM and LV concentration of atrial natriuretic factor (ANF) peptide and its corresponding mRNA transcript (despite the fact that other known markers of LVH correlated positively with LVM). At the time of our report, the gene coding for ANF (natriuretic peptide precursor A [Nppa]) was known as one for which the expression was affected both quickly and reliably in response to hypertrophic stimuli, to the point that increased Nppa expression was considered almost synonymous with LVH. It was, therefore, relatively surprising to observe that Nppa expression could dissociate from LVM. However, experiments in mice had shown that inactivation of either Nppa or Npr1 (the gene coding for the ANF receptor) results in increased LVM that is disproportionate compared with the accompanying increase in blood pressure. Altogether, it thus appeared that early activation of Nppa by hypertrophic stimuli might in fact represent a cardioprotective response and, conversely, that deficits in Nppa signaling might associate with an increased hypertrophic response. We further showed that WKHA rats harbored a single nucleotide polymorphism in the Nppa minimal promoter region that reduced its transcriptional activity. Likewise, the Nppa locus was within the confidence interval of the overlapping quantitative trait loci linked to either LV ANF expression or LVM (identified by the symbol Cm24 in the Rat Genome Database) in the male progeny of WKHA/WKY crosses. These linkage results were further validated by physical mapping in congenic rats, where introgression of the Nppa/Cm24 locus from WKHA rats into the WKY background both decreased LV ANF concentration and increased the size of cardiac ventricular myocytes. Of note, the Nppa/Cm24 locus was linked to LV ANF concentration in both the male and female progeny of WKHA/WKY crosses, but it showed linkage to LVM only in male rats.

Beyond the effect of the Nppa/Cm24 locus on LVM under basal conditions, we wanted to test whether this locus may associate with cardiac outcome under pathological conditions. We, therefore, challenged the hearts of WKYs and their congenic WKY.WKHA-Cm24 counterparts by volume overload. Although this maneuver had either no or little effects in WKYs, it induced adverse LV remodeling and dysfunction in the hearts of their congenic counterparts harboring Cm24 from WKHA rats. Moreover, this effect of the Nppa/Cm24 locus on cardiac deterioration was found in both the male and female progeny, despite the fact that the locus did not link under basal conditions with LVM in the female progeny. This finding had 3 implications: (1) it illustrated the fact that the effect of a quantitative trait loci on a phenotypic trait may become manifest only under particular environmental conditions (in this case, the combination of sex and volume overload); (2) it provided a proof-of-principle demonstration that a naturally occurring variant of the Nppa gene may constitute a genetic risk factor linked to cardiac outcome; and (3) it showed that, beyond its effect on LVM under basal conditions, the Nppa pathway may have important cardioprotective effects in pathological conditions.

Cardioprotective Effects of ANF and/or Cyclic GMP

Inactivation of the ANF pathway could possibly affect LVM via either a local direct effects of ANF on the heart or the possible hemodynamic effects of decreased levels of circulating ANF. However, genetic alterations targeted specifically to the heart showed that inactivation of ANF increased LVM primarily via a cardiac-specific effect. Most of the biological actions of ANF are believed to be mediated via cyclic GMP (cGMP), for which intracardiac production is increased after the binding of ANF to its plasma membrane guanylate cyclase (GC) receptor (known as either NPR-A or GC-A). Consequently, to test whether the generation of cGMP within cardiomyocytes could also prevent LVH in vivo, we engineered transgenic (TG) mice that express a constitutively activated GC domain of the NPR-A receptor exclusively in cardiomyocytes, resulting in a selective increase in intracellular cGMP. Although expression of the transgene had no effect on cardiac performance under basal conditions, it attenuated the effects of either pharmacological or mechanical hypertrophic stimuli on both LVM and cardiomyocyte size. cGMP, thus, appeared to constitute a negative intrinsic modulator of the hypertrophic response. Can this signaling pathway, therefore, be exploited therapeutically to improve cardiac functions in pathological situations? The first indication in this regard came from the work of the group of D. Kass. They showed that pharmacological blockade of intracellular cGMP degradation by administration of the phosphodiesterase 5A inhibitor sildenafil also suppressed pressure overload-induced LVH and restored LV chamber function to normal. The applicability of cGMP-dependent cardioprotection may apply to cardiomyopathies other than that caused by pressure overload, as others have shown in mice that phosphodiesterase 5A inhibition with sildenafil preserves the deterioration of LV function after myocardial infarction by limiting necrosis and apoptosis and protects the heart against doxorubicin toxicity. Recently, we have tested whether this approach could also improve the cardiomyopathy cause by dystrophin deficiency in mice carrying the mdx mutation. When cGMP signaling was enhanced either pharmacologically (with sildenafil treatment) or genetically (by crossing mdx mice with our heart-specific GC TGs), it was possible to improve the contractile performance, myocardial metabolic status, and sarcolemmal integrity of dystrophic hearts.

Other cGMP-Generating Pathways

In addition to the stimulation of plasma membrane GC receptors and the regulation of intracellular degradation, increases in intracellular cGMP may result from activation of other signaling pathways. Most notably, cytoplasmic soluble GC can be activated by gaseous substances, such
as carbon monoxide, and mostly NO, the latter being produced by a family of enzymes known as NO synthases (NOSs). There are 3 different genes coding for 3 distinct isoforms of NOS, that is, neuronal NOS (also known as NOS1), inducible NOS (or NOS2), and endothelial NOS (or NOS3). All 3 NOS isoforms can be found in cardiomyocytes, although NOS1 and NOS3 are expressed constitutively, whereas NOS2 is induced by stimulation by cytokines.31,32 Although not all cellular actions of NO are mediated by cGMP, genetic alteration of the expression of NOS genes in either knockout or TG mice has shown that NOS affects LVM and cardiomyocyte size in a manner parallel to the effects seen with alterations of the ANP signaling pathway. Thus, NOS3−/− mice display increased LVM and cardiomyocyte volume (as compared with their wild-type counterparts) during aging,33 during the postmyocardial infarction period,34 or after pressure overload,35 whereas overexpression of NOS3 in TG mice attenuates the hypertrophic effects of chronic isoproterenol infusion.36 In NOS1−/− mice, LVM and cardiomyocyte volume are increased when compared with wild-type counterparts in the absence of any change in blood pressure.37 Although the above genetic manipulations were not cardiac specific, experiments using isolated cardiomyocytes from the same animals showed that the cardiac effects of NOS may result (at least in part) from local actions.37

The importance of these other signaling pathways relates in part to the fact that they provide other avenues by which intracellular cGMP concentration can be modulated pharmacologically. For instance, it has been reported that a drug that is an orally active stimulator of soluble GC can reduce angiotensin II–induced cardiac remodeling.38 Likewise, inhalation therapy with low doses of carbon monoxide has been shown to improve doxorubicin-induced cardiomyopathy in part via stimulation of soluble GC.39 Of note, in the particular cases of dystrophin deficiency and doxorubicin toxicity, it is believed that deficits in NO- and/or ANP-mediated signaling are partly causal to the disease30,39 and may, thus, represent examples where enhancing cGMP signaling may prove particularly effective. However, one important additional caveat in the interpretation of the results obtained with genetically modified animals is the fact that subcellular pools of cGMP are determined by the respective locations of soluble and particular GCs and phosphodiesterases.40 For instance, cGMP derived from either NOS1 or NOS3 affects cardiac contractility in very different ways.37

Mechanisms Mediating the Cardioprotective Actions of cGMP

Initial studies on the mechanisms of action of cGMP in the cardiovascular system have dealt mostly with its actions in vascular smooth muscle cells, endothelial cells, and/or platelets.41–44 However, given the more recent findings on the cardiac effects of cGMP, there is now increasing information concerning its mechanisms of action in the heart.40,44 First, there seems to be agreement between studies using either pharmacological45 or genetic46,47 tools that the cardioprotective effects of cGMP are mediated by cGMP-dependent protein kinase (also known as protein kinase G [PKG]), with phosphorylation of extracellular signal–regulated kinase 1/2 appearing to be one important obligatory step.45,48,49 Of note, this dependency on PKG may be in contrast to some actions of cGMP elsewhere in the cardiovascular system, because it is, for instance, dispensable for the protective actions of cGMP in restenosis-associated vascular remodeling.50 Once PKG is activated in cardiac cells, its cardioprotective actions appear to result from effects on 2 main downstream systems. First, it improves calcium handling in cardiomyocytes,51 presumably via combined effects on phosphorylation of several sarcoplasmic proteins (including phospholamban, the inositol triphosphate receptor, and the ryanodine receptor) and calcium entry through L-type calcium channels40,51,52 and also possibly phosphorylation of a novel family of cation channels called “transient receptor potential proteins,”53 the latter having been implicated recently in cardiac hypertrophy.54 Intracellular calcium is well known to play central roles in the genesis and development of LVH.55 The other important target of cGMP within cardiomyocytes appears to be the mitochondria, because cGMP signaling prevents opening of the mitochondrial permeability transition pore via several convergent effects, including the following: (1) activation of the mitochondrial ATP-sensitive K channel56; (2) direct phosphorylation of an unidentified protein on the mitochondrial outer membrane56; and (3) upregulation of the antiaapoptotic protein Bcl-2.43,48 Finally, the protective effects of cGMP signaling in the heart are not restricted to only cardiomyocytes. For instance, cGMP exerts antifibrogenic effects by inhibiting the transforming growth factor-β–induced transformation of fibroblasts into myofibroblasts via PKG-dependent phosphorylation of Smad3 in these cells.58

Because cGMP acts on multiple effectors, the spectrum of its cardioprotective actions appears to be fairly large, which is compatible with the fact that it improves both cardiac remodeling and function in several types of cardiomyopathies. In addition, there may be redundancy between these various pathways. For instance, although calcineurin is (downstream of increased cellular calcium) one of the primary targets mediating the antihypertrophic effects of cGMP–PKG signaling,46,59 the antihypertrophic effects of this pathway are maintained in the hearts of knockout mice effectively lacking calcineurin activity.56 Between studies, there are also sometimes discrepancies between some of the modes of actions of cGMP, one possible cause being that the cardioprotective effects of cGMP have been examined in different types of cardiomyopathies (eg, ischemic or pressure overload cardiomyopathies) and that there may some differences between the various models used. Nonetheless, a better understanding of the mode of action of cGMP may lead to new therapeutic modalities for the treatment of cardiac dysfunction.

Genetic Determinants of Cardiovascular Risk

Given the high heritability of LVM, there are ongoing efforts to identify gene variants that contribute to the variance of this trait. Accordingly, a recent linkage study has reported on
chromosome regions linked to LVM,\textsuperscript{61} whereas a meta-analysis of genome-wide association studies has identified several genetic loci linked to either LV mass or geometry.\textsuperscript{62} There was no indication in either study of association or linkage with genes associated with the generation of intracellular cGMP. Nonetheless, the latter trait can be controlled by a variety of genes. For instance, in addition to the ones discussed in the above paragraphs, precursors to natriuretic peptides are processed by the protease corin,\textsuperscript{63} are cleared from the circulation via the natriuretic peptide clearance receptor (encoded by \textit{Npr3}), and are metabolized in the circulation by the membrane metallo-endopeptidase (encoded by \textit{Mme}). Interestingly, a polymorphism within the \textit{corin} gene and found almost exclusively in black individuals has been reported to associate with LVM in subjects with hypertension.\textsuperscript{64} In addition, circulating levels of natriuretic peptides are themselves under genetic control. Accordingly, common genetic variants within the \textit{NPPA-NPPB} locus have been found to associate with circulating natriuretic peptide concentrations.\textsuperscript{65} In the future, if genes associated with the cGMP/PKG pathway turn out to associate with LVM, detection of corresponding variants may be helpful to stratify cardiovascular risk in patients or to identify patients most susceptible to benefit from therapies that enhance cGMP signaling.

\textbf{From Animal Models to Human Studies}

Altogether, the combined investigations on animal strains carrying natural variants of \textit{Nppa} on their corresponding congenic strains and on either TG or knockout mice have done the following: (1) made it possible to discover the cardioprotective effects of cGMP; (2) enabled studies aimed at understanding the mechanisms of action of cGMP; and (3) provided models to test the therapeutic potential of the cGMP/PKG pathways. These studies have progressed to the point that the National Institutes of Health have recently initiated a multicenter clinical trial of sildenafil for the treatment of heart failure with preserved ejection fraction (\texttt{www.clinicaltrials.gov identifier NCT00763867}). Moreover, genome-wide association studies performed in human populations are beginning to report on genetic loci that associate with LVM. Despite these successes, we are still limited in our ability to understand how variants discovered by genome-wide association studies influence complex traits, and one of the challenges going forward will be to identify the biological context in which these statistically significant candidate variants act.\textsuperscript{66} In this regard, genetic animal models will continue to constitute invaluable tools, either to discover naturally occurring genetic variants influencing complex traits or to complement genome-wide association studies to discover which genes within a given region are linked mechanistically to a given trait.

\textbf{Sources of Funding}

This work was supported by grant MOP-74460 from the Canadian Institutes of Health Research.

\textbf{Disclosures}

None.

\textbf{References}


23. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bulikat A, Begrov F, Scheider MD, Garbers DL, Kuhn M. Pressure-independent cardiac...


Cardioprotective Actions of Cyclic GMP: Lessons From Genetic Animal Models
Christian F. Deschepper

Hypertension. 2010;55:453-458; originally published online December 14, 2009; doi: 10.1161/HYPERTENSIONAHA.109.145235

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/55/2/453